IFIT3 specifically targets programmed death ligand 1 (PD-L1) expression by activating the PI3K/AKT signaling pathway, thereby regulating the epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) activity. The gene discussed is IFIT3; the disease is cancer.